Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
Public ClinicalTrials.gov record NCT00825955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
Study identification
- NCT ID
- NCT00825955
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 587 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2009 (Actual)
- Primary completion
- Nov 15, 2011 (Actual)
- Completion
- Aug 25, 2017 (Actual)
- Last update posted
- Oct 9, 2019
2009 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Univ Of Ark For Med Sci | Little Rock | Arkansas | 72205 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92350 | — |
| Richard Finn, M.D. | Los Angeles | California | 90095-7077 | — |
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| Pacific Hematology Oncology Associates | San Francisco | California | 94115 | — |
| UF Health Clinical Research Center | Gainesville | Florida | 32610 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| 3912 Taubman Center | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System Irb | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Mount Sinai School Of Medicine | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health & Sci Univ | Portland | Oregon | 97239 | — |
| University Of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University Of Texas | Houston | Texas | 77030 | — |
| The University Of Texas Health Science Center | San Antonio | Texas | 78229 | — |
| Mcguire Dvamc | Richmond | Virginia | 23249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00825955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00825955 live on ClinicalTrials.gov.